- Home
- CR vs SRPT Comparison
CR vs SRPT Comparison
Compare CR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- SRPT
- Stock Information
- Founded
- CR 1855
- SRPT 1980
- Country
- CR United States
- SRPT United States
- Employees
- CR N/A
- SRPT N/A
- Industry
- CR Metal Fabrications
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- CR Industrials
- SRPT Health Care
- Exchange
- CR Nasdaq
- SRPT Nasdaq
- Market Cap
- CR 8.9B
- SRPT N/A
- IPO Year
- CR N/A
- SRPT 1997
- Fundamental
- Price
- CR $169.11
- SRPT $37.57
- Analyst Decision
- CR Strong Buy
- SRPT Buy
- Analyst Count
- CR 5
- SRPT 23
- Target Price
- CR $177.40
- SRPT $131.09
- AVG Volume (30 Days)
- CR 389.5K
- SRPT 3.8M
- Earning Date
- CR 04-28-2025
- SRPT 05-06-2025
- Dividend Yield
- CR 0.54%
- SRPT N/A
- EPS Growth
- CR 54.50
- SRPT N/A
- EPS
- CR 5.76
- SRPT N/A
- Revenue
- CR $2,178,600,000.00
- SRPT $2,233,371,000.00
- Revenue This Year
- CR $9.52
- SRPT $64.51
- Revenue Next Year
- CR $6.34
- SRPT $22.40
- P/E Ratio
- CR $29.83
- SRPT N/A
- Revenue Growth
- CR 17.22
- SRPT 59.15
- 52 Week Low
- CR $127.04
- SRPT $35.46
- 52 Week High
- CR $188.52
- SRPT $173.25
- Technical
- Relative Strength Index (RSI)
- CR 68.94
- SRPT 27.67
- Support Level
- CR $164.63
- SRPT $35.46
- Resistance Level
- CR $169.51
- SRPT $64.80
- Average True Range (ATR)
- CR 5.02
- SRPT 3.68
- MACD
- CR 2.74
- SRPT -1.45
- Stochastic Oscillator
- CR 93.60
- SRPT 13.12
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.